MCO Molecular and Clinical Oncology 2049-9450 2049-9469 D.A. Spandidos 10.3892/mco.2016.1027 MCO-0-0-1027 Articles Neoplastic fever in patients with bone and soft tissue sarcoma NakamuraTomoki MatsumineAkihiko MatsubaraTakao AsanumaKunihiro SudoAkihiro Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan Correspondence to: Dr Tomoki Nakamura, Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan, E-mail: tomoki66@clin.medic.mie-u.ac.jp 11 2016 21 09 2016 5 5 631 634 28012016 02082016 Copyright © 2016, Spandidos Publications 2016

The development of fever is a common complication in the clinical course of cancer. If all other potential causes of fever are excluded, the possibility of neoplastic fever should be considered. The aim of the present study was to determine the incidence of neoplastic fever in patients with bone and soft tissue sarcomas. Between January 2009 and December 2014, 195 patients with bone and soft tissue sarcoma (111 men and 84 women; mean age, 55 years) were admitted to the Department of Orthopaedic Surgery of Mie University Graduate School of Medicine (Tsu, Japan). Episodes of fever were observed in 58 patients (30%), of whom 11 (5.5%) had neoplastic fever (mean maximum temperature, 38.9°C). The causes of neoplastic fever were as follows: Primary tumor (n=3), local recurrence (n=1), metastasis (n=5), and local recurrence with metastasis (n=2). Of the 11 patients, 9 were treated with naproxen and 8 exhibited a complete response, with their temperature normalizing to <37.3°C within 24 h. The 2 patients who were not treated with naproxen underwent surgical tumor resection, which resulted in prompt and complete lysis of the fever. In conclusion, neoplastic fever occurred in 5.5% of the 195 patients with bone and soft tissue sarcomas investigated herein. Naproxen may be effective for treating neoplastic fever in patients with bone and soft tissue sarcoma; however, radical tumor treatment may have to be considered to achieve permanent lysis of the fever.

 neoplastic fever naproxen soft-tissue sarcoma bone sarcoma Introduction

The development of fever is a common complication in the clinical course of cancer (1–4). It is crucial to determine the origin of fever, as patients are managed differently depending on the cause. Neutropenic fever is a common occurrence in patients with neutropenia after intensive chemotherapy (1–3). Neutropenic fever reportedly occurs in 37% of patients with osteosarcoma (5), 17–26% of patients with Ewing's sarcoma (6) and 8–54 of those with soft tissue sarcoma (7–9). Furthermore, patients with bone and soft tissue sarcomas are at risk of surgical site infection, which was reported to occur in 6–15% of those patients who undergo surgery (10–12). Even in the absence of surgical site infection and neutropenia, febrile complications often develop (1–4,13,14). Fever may be caused by diagnostic and/or therapeutic procedures, including medications, transfusions, surgical procedures, hematoma and thrombosis (1–4,13,14). If all the potential causes of fever are excluded, the possibility of neoplastic fever should be considered (13,15,16). Neoplastic fever is a paraneoplastic syndrome that is encountered in 5% of cancer patients (17). There have been a few case reports on neoplastic fever among patients with bone and soft tissue sarcomas (18–20). The purpose of the present study was to investigate the occurrence of febrile episodes defined as neoplastic fever in patients with bone and soft tissue sarcomas during treatment and follow-up.

 Patients and methods <sec> <title>Subjects

Between January 2009 and December 2014, 195 patients with bone and soft tissue sarcomas were admitted to the Department of Orthopaedic Surgery of Mie University Graduate School of Medicine (Tsu, Japan). Patients who were diagnosed based on biopsy results alone and those who were admitted for best supportive care without surgical resection, chemotherapy and/or radiotherapy, were excluded. The study cohort comprised 111 men and 84 women with a mean age of 55 years. The primary sarcoma originated from the soft tissue in 147 patients and from the bone in 48 patients. The main histological diagnoses of malignant bone tumors were osteosarcoma (n=24), chondrosarcoma (n=10) and Ewing's sarcoma (n=8), while the main histological diagnoses of soft tissue sarcomas were well-differentiated liposarcoma (n=33), myxofibrosarcoma (n=21), undifferentiated pleomorphic sarcoma (n=19) and leiomyosaroma (n=16). Surgical resection for the primary tumor was performed in 158 patients and for recurrence or metastasis in 17 patients. During the clinical course, chemotherapy and radiation therapy were administered to 55 and 50 patients, respectively.

 Diagnosis

Neoplastic fever was diagnosed according to the following criteria: i) A single temperature measurement of >38.3°C (101°F) or a temperature of >38.0°C (100.4°F) sustained for >1 h (21), ii) duration of fever for 72 h, iii) no evidence of infection on clinical and laboratory examinations, including blood (± urine and sputum) culture and iv) no evidence of infection on enhanced computed tomography (10,14). Informed consent was obtained from all the patients included in this study.

 Statistical analysis

The statistical association of the blood examinations was evaluated using the paired Student's t-test. P<0.05 was considered to indicate statistically significant differences. The Stat View statistical software package, version 5.0 (SAS Institute, Cary, NC, USA) was employed for analysis.

 Results <sec> <title>Patients

Episodes of fever were observed in 58 of the 195 patients (30%), of whom 11 were determined as having neoplastic fever (Table I). These patients included 4 men and 7 women, with a mean age of 44 years. The tumor sites responsible for the development of neoplastic fever were as follows: Primary tumor (n=3); local recurrence (n=1); metastasis (n=5); and local recurrence with metastasis (n=2). The mean of the maximum temperature in the 11 patients was 38.9°C (range: 38.3–39.6°C).

 Treatment and outcome

Of the 11 patients, 9 were treated with naproxen, as complete lysis of fever was not achieved in 8 patients who received loxoprofen and 1 patient who received acetaminophen (Table II). Naproxen was orally administered at a dose of 300–600 mg per day. Prior to the administration of naproxen, the white blood cell count ranged from 3,870 to 11,120/mm3 (mean, 8,131/mm3) and the C-reactive protein (CRP) levels ranged from 5.52 to 24.84 mg/dl (mean, 13.4 mg/dl). The serum interleukin-6 (IL-6) level was measured and found to be elevated in 5 of the 11 patients (normal, <4.0 pg/ml; Table I). Of the 9 patients, 8 achieved a complete response with naproxen, with their temperature normalizing to <37.3°C within 24 h. Subsequently, 4 of the 9 patients underwent tumor resection. Further naproxen treatment was not required for these 4 patients after surgery, as they did not develop fever. One of the 9 patients achieved a complete response with chemotherapy (ifosfamide, 12 g/m2) and did not require naproxen as there was no fever. In one patient, it was necessary to reduce the dose of naproxen from 300 to 200 mg per day, as the patient exhibited renal function decline and had no response to naproxen; after 2 months, the patient succumbed to peritoneal metastases without recovering from the fever. Naproxen treatment was continued in the 3 remaining patients, until eventually they succumbed to their disease.

The 2 patients who were not treated with naproxen underwent surgical tumor resection and showed prompt and complete lysis of the fever.

Three days after the administration of naproxen, the white blood cell count varied from 3,320 to 15,200/mm3 (mean, 7,079/mm3) and the CRP levels varied from 4.26 to 22.55 mg/dl (mean, 12.76 mg/dl). There was no significant difference between the mean white blood cell count or the mean CRP levels prior to and after the administration of naproxen (P=0.29 and 0.78, respectively).

At the time of final review (February, 2016) 1 patient remained alive without disease, whereas 10 patients had succumbed to their disease.

 Discussion

The present study assessed the incidence of neoplastic fever during the clinical course of bone and soft tissue sarcoma patients.

Neoplastic fever, which is defined as fever caused by cancer itself, has been shown to be the most common cause of fever of unknown origin in cancer patients, particularly lymphoma and leukemia patients (13,14,17). Neoplastic fever is relatively rare in patients with bone and soft tissue sarcomas, with only few cases reported to date (18–20,22). In the present study, neoplastic fever occurred in 11 of 195 patients with bone and soft tissue sarcomas (5.5%). Browder et al (17) reported that 30% of cancer patients develop fever, and that in 5% of the patients, the fever has no explanation other than paraneoplastic syndrome. Thus, neoplastic fever should be considered when all other possible causes of fever are excluded. Neoplastic fever often affects the patients' quality of life and may necessitate antipyretic treatment. The antipyretic effect of corticosteroids on neoplastic fever was compared to that of naproxen (23), and it was noted that naproxen treatment resulted in complete lysis of the fever in 90% of febrile patients; by contrast, complete lysis of fever was only achieved in 50% of the patients who were treated with corticosteroids. Although the patient number was limited and the design of the study was retrospective, the authors concluded that naproxen was more effective for the treatment of neoplastic fever compared with corticosteroids (23).

To the best of our knowledge, there have been no reports on the effect of naproxen on neoplastic fever in patients with bone and soft tissue sarcomas to date. In the present study, naproxen was administered to 9 of the 11 patients with neoplastic fever; 8 of the 9 patients exhibited a complete response, with their body temperature normalizing to <37.3°C within 24 h. Thus, naproxen may be effective for treating neoplastic fever in patients with bone and soft tissue sarcoma prior to radical treatment or during best supportive care. There was no significant change in the white blood cell count or the CRP levels prior to and after naproxen treatment. There are several possible mechanisms for the production of inflammatory markers, such as CRP and IL-6 (24–26). Tumor growth may cause tissue inflammation (24). Tumor-associated mononuclear cells may produce IL-6 as an immune cytokine response to tumor growth (25). Cancer cells may increase the production of inflammatory proteins (26). Tumor growth cannot be reduced by naproxen; therefore, radical tumor treatment is required to improve these hematological abnormalities. Although there were no complications in the cases presented in this study, naproxen should be used with caution as it has been associated with platelet dysfunction and gastrointestinal side effects (27). Furthermore, the antipyretic effect of other non-steroidal anti-inflammatory drugs on neoplastic fever may be comparable to those of naproxen. A randomized trial including 48 cases reported that indomethacin and diclophenac sodium were equally effective regarding their antipyretic properties, whereas naproxen had the most rapid effect (28). A large-scale study is required to confirm these findings.

The present study had certain limitations. First, although outpatients were referred to our hospital if they exhibited persistent symptoms, we were unable to estimate the episodes of fever occurring among outpatients. Another limitation of the present study is its retrospective nature. However, the present study expands the knowledge on the epidemiology and outcome of neoplastic fever in patients with bone and soft tissue sarcomas.

In conclusion, neoplastic fever occurred in 5.5% of the 195 patients with bone and soft tissue sarcomas. Naproxen may be effective for treating neoplastic fever in such patients; however, radical tumor treatment may have to be considered to achieve complete and continuous fever lysis without using any antipyretic drugs.

 References ToussaintEBahel-BallEVekemansMGeorgalaAAl-HakakLPaesmasnsMAounMCause of fever in cancer patients (prospective study over 477 episodes)Support Care Cancer14763769200610.1007/s00520-005-0898-016528534 NachmanJBHonigGRFever and neutropenia in children with neoplastic disease: An analysis of 158 episodesCancer45407412198010.1002/1097-0142(19800115)45:2<407::AID-CNCR2820450237>3.0.CO;2-S7351024 PaganoLCairaMRossiGTumbarelloMFanciRGarziaMGVianelliNFilardiNDe FabritiisPBeltrameAA prospective survey of febrile events in hematological malignanciesAnn Hematol91767774201210.1007/s00277-011-1373-222124621 ParkSKangCIChungDRPeckKRKimWSKimSJClinical significance of non-neutropenic fever in the management of diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Comparison with febrile neutropenia and risk factor analysisCancer Res Treat47448457201510.4143/crt.2014.03425648098 BacciGFerrariSLonghiAPicciPMercuriMAlvegardTASaeterGDonatiDManfriniMLariSHigh-dose ifosfamide in combination with high-dose methotrexate, adriamycin and cysplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot studyJ Chemother14198206200210.1179/joc.2002.14.2.19812017378 LewinJWieringaSCollinsMDesaiJOrmeLLingaratnamSThomasDMIntra-patient dose escalation in Ewing's sarcoma treated with vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide: A retrospective reviewClin Sarcoma Res315201310.1186/2045-3329-3-1524321600 SchmittTLehnerBKasperBBischofMRoederFDietrichSDimitrakopoulou-StraussAStraussLGMechtersheimerGWuchterPA phase II study evaluating neo/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcomaBMC Cancer11510201110.1186/1471-2407-11-51022152120 KalofonosHPKourousisCKaramouzisMVIconomouGTsiataETzorzidisFMegasPLambirisEGeorgouliasVA phase II study of docetaxel and epirubicin in advanced adult soft tissue sarcomas (STS)Sarcoma8129133200410.1155/2004/57303518521407 JudsonIVerweijJGelderblomHHartmannJTSchöffskiPBlayJYKerstJMSufliarskyJWhelanJHohenbergerPDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trialLancet Oncol15415423201410.1016/S1470-2045(14)70063-424618336 MoriiTMochizukiKTajimaTIchimuraSSatomiKSurgical site infection in malignant soft tissue tumorsJ Orthop Sci175157201210.1007/s00776-011-0179-322120702 NakamuraTMatsumineAMatsubaraTAsanumaKUchidaASudoAClinical characteristic of patients with large and deep soft tissue sarcomasOncol Lett10841844201526622580 NakamuraTMatsumineAUchidaAKawaiANishidaYKunisadaTArakiNSugiuraHTomitaMYokouchiMClinical outcomes of Kyocera Modular Limb Salvage System after resection of bone sarcoma of distal part of the femur: The Japanese Musculoskeletal Oncology Group StudyInt Orthop38825830201410.1007/s00264-013-2151-724158239 ZellJAChangJCNeoplastic fever: A neglected paraneoplastic syndromeSupport Care Cancer13870877200510.1007/s00520-005-0825-415864658 DinarelloCABunnPAJrFeverSemin Oncol2428829819979208885 ChangJCGrossHMNeoplastic fever responds to the treatment of an adequate dose of naproxenJ Clin Oncol355255819853981226 JohnsonMNeoplastic feverPalliat Med10217224199610.1177/0269216396010003068817592 BrowderAAHuffJWPetersdorfRGThe significance of fever in neoplastic diseaseAnn Intern Med55932942196110.7326/0003-4819-55-6-93213873560 OsakaSFujimotoYYamazakiHSuzukiKSawadaSHayashiNInterleukin-1 alpha producing synovial sarcoma with prolonged fever: A case reportJpn J Clin Oncol28436440199810.1093/jjco/28.7.4369739785 HamadaTKomiyaSHiraokaKZenmyoMMorimatsuMInoueAIL-6 in a pleomorphic type of malignant fibrous histiocytoma presenting high feverHum Pathol29758761199810.1016/S0046-8177(98)90288-X9670836 OsakaSHayakawaSYoshidaYSakuradaERyuJSugitaniMInterleukin-8 producing malignant fibrous histiocytoma with prolonged feverActa Histochem Cytochem391721200610.1267/ahc.0505317460768 FreifeldAGBowEJSepkowitzKAthe Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of AmericaClin Infect Dis52e56e93201110.1093/cid/cir07321258094 KiyosawaTHigakiHNakayamaYLiposarcoma associated with fever and reversible hepatic dysfunctionInt J Dermatol36132134199710.1111/j.1365-4362.1997.tb03073.x9109013 ChangJCAntipyretic effect of naproxen and corticosteroids on neoplastic feverJ Pain Symptom Manage3141144198810.1016/0885-3924(88)90159-53262142 CoussensLMWerbZInflammation and cancerNature420860867200210.1038/nature0132212490959 MantovaniGMaccioAPisanoMTumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patients autologous PBMCs are capable of releasing high amounts of various cytokinesInt J Cancer71724731199710.1002/(SICI)1097-0215(19970529)71:5<724::AID-IJC6>3.0.CO;2-T9180137 NakanishiHYoshikawaKJoyamaSInterleukin-6/soluble interleukin-6 receptor signaling attenuated proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell lineAm J Pathol165471480200410.1016/S0002-9440(10)63312-315277221 KathulaSKShahKPolenakovikHKoduriJCyclo-oxygenase II inhibitors in the treatment of neoplastic feverSupport Care Cancer11258259200312673465 TsavarisNZinelisAKarabelisSBeldecosDBacojanisCMilonacisNKarvounisNKosmidisPA randomized trial of the effect of three non-steroid anti-inflammatory agents in ameliorating cancer-induced feverJ Intern Med228451455199010.1111/j.1365-2796.1990.tb00262.x2254714

Characteristics of patients with neoplastic fever.

Age/gender Diagnosis Cause of fever Maximum temp (°C) IL-6 (pg/ml)a Naproxen treatment Treatment for tumors
26/F Clear cell sarcoma Lymph mets 39.6 209 Yes None
13/F Osteosarcoma LR and lung mets 39.6 NA No Op
46/M Ewing's sarcoma Primary tumor 38.6 NA Yes Op, Cx
16/M Osteosarcoma Primary tumor 39.0 34.8 Yes Op, Cx
26/M Ewing's sarcoma Lung mets 39.0 NA Yes Cx
72/F Leiomyosarcoma Pelvic mets 38.5 NA Yes None
24/F Epithelioid sarcoma LR and lung mets 39.1 NA Yes None
61/M Leiomyosarcoma Stomach mets 38.3 NA No Op, Cx
42/F UPS of bone Lung and pancreas mets 39.2 16.7 Yes Cx
81/F MPNST LR 39.0 34.4 Yes Op
71/F Fibrosarcoma Primary tumor 38.7 219 Yes Op

Normal levels, <4.0 pg/ml. MPNST, malignant peripheral nerve sheath tumor; LR, local recurrence; mets, metastasis; F, female; M, male; UPS, undifferentiated pleomorphic sarcoma; Op, operation; Cx, chemotherapy; temp, temperature; IL, interleukin; NA, not available.

Characteristics of patients who received naproxen treatment.

Prior to naproxen 3 days after naproxen
Age/gender WBC (/mm3) CRP (mg/dl) Dose of naproxen (mg/day) Response to naproxen WBC (/mm3)a CRP (mg/dl)b Duration of naproxen treatment (weeks)
26/F 10,350 11.48 300 No 10,610 22.55 2
46/M 3,870 5.52 400 Yes 3,790 7.12 4
16/M 11,000 14.83 300 Yes 6,140 4.26 3
26/M 8,180 13.07 400 Yes 4,090 12.85 1
72/F 10,640 9.95 400 Yes 15,200 13.28 3
24/F 11,120 9.8 300 Yes 8,720 8.27 3
42/F 5,030 24.84 300 Yes 3,320 18 6
81/F 8,800 14.34 300 Yes 7,410 8.05 1
71/F 4,190 16.82 600 Yes 4,430 20.46 2

Normal, 3,300–8,600/mm3.

Normal, <0.3 mg/dl. WBC, white blood cell count; CRP, C-reactive protein; F, female; M, male.